Key Highlights

  • On November 5, 2026 Silence Therapeutics (NASDAQ:SLN) ended at USD 19.76. The stock has climbed 95.21% across one month, 65.18% across three months, 188.39% across six months and 219.14% since the start of the year, although the session itself slipped 0.23%.
  • Ranked by one-month performance among 1,259 screened small caps, the company holds third place, with a Market Value between 300 million and 2 billion USD, while its one-week advance came to 0.23%.
  • Divesiran's Phase 2 SANRECO study in polycythemia vera reached its primary endpoint on August 10, 2026, producing an 88% clinical response versus 19% on placebo, and the shares rose 35.3% on that session.
  • Quarter-end cash stood at USD 72.1 million on June 30, 2026. Quarterly losses shrank to USD 12.3 million from USD 27.4 million, and the company had 141,739,180 ordinary shares outstanding.

Divesiran Data as the Core Fundamental Event

Roughly USD 10.12 would have been the price a month before November 5, 2026, by simple arithmetic on the 1M change. Silence Therapeutics (NASDAQ:SLN) gained 0.23% over the latest week and lost 0.23% in the session. The reviewed material reveals no single catalyst inside the past month. The principal fundamental development is the August 10, 2026 topline readout, which falls within the 3M and 6M windows. Dosing every six weeks yielded a 93.8% response and dosing every twelve weeks 81.3%; mean phlebotomies per patient were 0.2 compared with 2.1 on placebo, and no fresh safety signals appeared among the 48 phlebotomy-dependent participants.

Phase 3 Plans and Partnered Programs

Clinical readouts usually drive biotech valuations. A randomized, placebo-controlled success in a rare blood disorder can improve approval prospects, bring a Phase 3 study into focus and strengthen the case for partners. Management intends to launch a Phase 3 study of quarterly dosing during the first half of 2027, while potential IND submissions for SLN365 and SLN098 are pencilled in for 2027. Partner AstraZeneca's SLN312 program displayed dose-dependent ANGPTL3 reductions in Phase 1. Cantor Fitzgerald set an Overweight stance on June 24, 2026, and HC Wainwright set Buy on March 13, 2026. Investor rotation toward biotech and buying momentum could also have fed the rally, though this is general context.

Cash Runway, Spending Cuts and Financing Risk

Year-to-date growth of 219.14% and a six-month gain of 188.39% mean the latest 95.21% month builds on a sizeable run. R&D expenses dropped to USD 9.1 million from USD 17.6 million during the second quarter, and G&A expense came in at USD 4.7 million. Revenue registered zero for the quarter, against USD 224 thousand a year earlier, and no runway estimate was offered in the material. Holding USD 72.1 million against a six-month net loss of USD 27.2 million, funding a Phase 3 effort may Demand fresh capital. Small caps often trade sparsely, quotes can be wide, and a few orders can shift the price.

Where Things Stand

The rally follows the divesiran Phase 2 data and persistent buying, and no fresh single catalyst surfaced for the latest month. Silence Therapeutics (NASDAQ:SLN) takes third place in the 1,259-name small cap one-month ranking, behind Bumble at 132.88% and Katapult at 113.46%. At USD 19.76, much success already appears priced in, so the Phase 3 launch, financing and trial delivery are the next checkpoints.